Holen Sie sich die Stockscreener-App
2.3703
0.42%
-0.0097
Schlusskurs vom Vortag:
$2.38
Offen:
$2.36
24-Stunden-Volumen:
16,488
Relative Volume:
0.02
Marktkapitalisierung:
$11.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.2906
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
-3.07%
1M Leistung:
-1.25%
6M Leistung:
-14.44%
1J Leistung:
-49.75%
1-Tages-Spanne:
$2.36
$2.42
1-Wochen-Bereich:
$2.31
$2.4495
52-Wochen-Spanne:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Vergleichen Sie PHIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.3703 | 11.95M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.62 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.10 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
289.00 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
What makes Phio Pharmaceuticals Corp. stock price move sharplySmart Growth Low Risk Picks - Newser
Why Phio Pharmaceuticals Corp. stock attracts strong analyst attentionDaily Swing Candidates - Newser
How Phio Pharmaceuticals Corp. stock performs during market volatilityFree Financial Group - Newser
Phio Pharmaceuticals Announces 2025 Annual Meeting Details - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 6.3% – Here’s Why - Defense World
Phio Pharma stock maintains buy rating as cancer trial advances By Investing.com - Investing.com UK
Phio's Skin Cancer Drug Shows 44% Complete Response Rate, Final Trial Phase Begins - Stock Titan
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Yahoo Finance
Phio Pharmaceuticals Announces Strategic Initiative and Leadership Changes - TipRanks
Phio Pharmaceuticals Appoints Lisa Carson As Principal Financial OfficerSEC Filing - MarketScreener
Research Analysts Set Expectations for PHIO FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PHIO Q2 Earnings? - Defense World
Phio Pharmaceuticals appoints new strategic and finance VPs By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints new strategic and finance VPs - Investing.com India
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - TradingView
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Phio Pharmaceuticals (NASDAQ:PHIO) Now Covered by HC Wainwright - Defense World
Phio Pharma (PHIO) Receives Buy Rating and $14 Price Target from HC Wainwright | PHIO Stock News - GuruFocus
H.C. Wainwright assumes coverage on Phio Pharma stock with Buy rating - Investing.com India
Phio Pharmaceuticals (PHIO) Gains 'Buy' Rating with Promising Pr - GuruFocus
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - The Globe and Mail
Why BioNTech Stock Soared Today - The Globe and Mail
Best Value Stocks to Buy for May 28th - The Globe and Mail
New Strong Buy Stocks for May 28th - The Globe and Mail
AI Momentum Stocks: 3 Breakout Companies (ASML, PLTR, AVGO) - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
2 ‘Strong Buy’ Small-Cap Stocks With Blockbuster Potential - The Globe and Mail
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Elon Musk Could Bring Nvidia Stock $20 Billion Worth of Good News - The Globe and Mail
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):